Fuksiewicz Malgorzata, Kotowicz Beata, Rutkowski Andrzej, Achinger-Kawecka Joanna, Wagrodzki Michal, Kowalska Maria M
1 Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
2 Department of Oncological Gastroenterology, Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818765209. doi: 10.1177/1533033818765209.
Colorectal cancer is one of the most common and significant malignancies in the world. YKL-40 (chitinase-3-like protein 1) is involved in cell proliferation, migration, inflammation, and tissue remodeling; and serum levels of YKL-40 are associated with patient outcome in various cancers. The aim of this study was to assess the potential clinical usage of YKL-40 pretreatment serum levels as a prognostic biomarker in rectal cancer.
Concentrations of YKL-40 and standard tumor marker-Carcinoembryonic antigen (CEA)-were assessed in serum of 83 patients with rectal cancer without distant metastasis, and association with clinicopathological characteristics and disease-free and overall survival was evaluated.
Concentration of YKL-40 was significantly higher in serum of patients with rectal cancer compared to healthy controls ( P = .0001), and YKL-40 levels were able to predict rectal cancer (area under the Receiver Operating Characteristic [ROC] curve = .769) with higher accuracy than CEA (area under the ROC curve = .728) in patients with early stage disease. Increased YKL-40 levels were significantly associated with age ( P = .001); however, no association with other clinicopathological characteristics was observed. Finally, in patients with recurrence, the percentage of cases with increased concentration of YKL-40 was significantly higher than in patients without recurrence ( P = .041), and Kaplan-Meier analysis demonstrated that elevated YKL-40 concentration is a predictor of poor overall survival in patients with rectal cancer.
Pretreatment serum levels of YKL-40 may be a novel prognostic factor of overall and disease-free survival in patients with nonmetastatic colorectal cancer.
结直肠癌是世界上最常见且严重的恶性肿瘤之一。YKL-40（几丁质酶-3样蛋白1）参与细胞增殖、迁移、炎症和组织重塑；YKL-40的血清水平与多种癌症患者的预后相关。本研究旨在评估YKL-40预处理血清水平作为直肠癌预后生物标志物的潜在临床应用价值。
对83例无远处转移的直肠癌患者血清中的YKL-40浓度和标准肿瘤标志物癌胚抗原（CEA）进行评估，并评估其与临床病理特征、无病生存期和总生存期的相关性。
与健康对照相比，直肠癌患者血清中YKL-40浓度显著更高（P = 0.0001），在早期疾病患者中，YKL-40水平预测直肠癌的准确性高于CEA（受试者工作特征曲线下面积分别为0.769和0.728）。YKL-40水平升高与年龄显著相关（P = 0.001）；然而，未观察到与其他临床病理特征的相关性。最后，在复发患者中，YKL-40浓度升高的病例百分比显著高于未复发患者（P = 0.041），Kaplan-Meier分析表明，YKL-40浓度升高是直肠癌患者总生存期较差的预测指标。
YKL-40预处理血清水平可能是非转移性结直肠癌患者总生存期和无病生存期的新型预后因素。
